Literature DB >> 12479846

Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies.

A Carral1, J de la Rubia, G Martín, S Mollá, J Martínez, G F Sanz, M A Soler, I Jarque, C Jiménez, M A Sanz.   

Abstract

Factors influencing the collection of autologous peripheral blood stem cells (PBSCs) were studied in 182 mobilization procedures performed on 145 consecutive patients with acute myeloblastic leukemia (AML; n=67) and with various non-myeloid malignancies (NMM; n=78). PBSC were collected following mobilization with chemotherapy, treatment with granulocyte colony-stimulating factor (G-CSF) or chemotherapy plus G-CSF. Fewer colony-forming unit granulocyte-macrophages (CFU-GMs) were collected from patients with AML than from patients with NMM (P<0.0001), although there were no differences in the numbers of CD34+ cells collected between both groups. Multiple regression analysis showed that chemotherapy alone was predictive of a low CD34+ yield in patients with NMM (regression coefficient (RC)=-2.1; P=0.003). In addition, the interactions "diagnosis mutliple myeloma (MM)xmobilization with chemotherapy" (RC=2.9; P=0.004) and "diagnosis MMxmobilization with chemotherapy plus G-CSF" (RC=2.1; P=0.04) also remained in the model, both showing a favorable influence. In AML, mobilization with chemotherapy plus G-CSF was associated with higher CD34+ yields (P=0.003). In this subgroup of patients, multiple regression analysis identified the number of cycles of previous chemotherapy (< or =2 cycles; RC=1.3; P=0.03) and peripheral blood counts (WBC > or =1.5 x 10(9)/l and monocytes >20%; RC=0.8; P=0.02) as the factors most predictive of CD34+ cell yield. These findings emphasize the need to optimize harvesting technique to enhance safety and minimize morbidity and costs of this valuable procedure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12479846     DOI: 10.1016/s0145-2126(02)00068-1

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

Review 1.  Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand.

Authors:  Louis M Pelus
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

2.  Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission.

Authors:  Jeeyun Lee; Mark H Lee; Keon Woo Park; Jung Hoon Kang; Do Hyung Im; Kihyun Kim; Se-Hoon Lee; Won Seog Kim; Jinny Park; Chul Won Jung; Keunchil Parka
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

3.  Peripheral blood stem cell collection after intermediate-dose cytarabine in adult patients with acute myeloblastic leukemia undergoing autologous blood stem cell transplantation in first complete remission.

Authors:  J de la Rubia; G Martín; J Martínez; I Lorenzo; G Sanz; I Jarque; F Moscardó; C Jiménez; P Lorente; A Camps; M A Sanz
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

4.  A hospital based retrospective study of factors influencing therapeutic leukapheresis in patients presenting with hyperleukocytic leukaemia.

Authors:  Yanxia Jin; Shishang Guo; Qin Cui; Sichao Chen; Xiaoping Liu; Yongchang Wei; Yunbao Pan; Liang Tang; Tingting Huang; Hui Shen; Guanghui Xu; Xuelan Zuo; Shangqin Liu; Hui Xiao; Fei Chen; Fayun Gong; Fuling Zhou
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

5.  Small-Molecule Ice Recrystallization Inhibitors Improve the Post-Thaw Function of Hematopoietic Stem and Progenitor Cells.

Authors:  Jennie G Briard; Suria Jahan; Priya Chandran; David Allan; Nicolas Pineault; Robert N Ben
Journal:  ACS Omega       Date:  2016-11-28

6.  Optimal time to start peripheral blood stem cell collection in children with high-risk solid tumors.

Authors:  Ki Woong Sung; Hee Won Chueh; Na Hee Lee; Dong Hwan Kim; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo; Eun Suk Kang; Dae Won Kim
Journal:  J Korean Med Sci       Date:  2013-12-26       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.